Fangsheng Pharmaceutical announced that on November 9, 2026, the company signed a “Drug Marketing License Transfer Agreement” with Euler Pharmaceuticals to accept the marketing licenses it holds for “acetylcysteine granules” and “iprazole enteric tablets”. The R&D investment for acetylcysteine granules was 5.5 million yuan, and the R&D investment for eprazole enteric tablets was 12.62 million yuan. Acetylcysteine granules obtained a drug registration certificate in June 2026. Iprazole enteric tablets have been registered for approval, and none of the above drugs have yet been produced or sold. This transaction does not constitute a related transaction, nor does it constitute a major asset restructuring. It does not require review and approval by the board of directors or shareholders' meeting within the authority of the chairman of the board of directors.

Fangsheng Pharmaceutical announced that on November 9, 2026, the company signed a “Drug Marketing License Transfer Agreement” with Euler Pharmaceuticals to accept the marketing licenses it holds for “acetylcysteine granules” and “iprazole enteric tablets”. The R&D investment for acetylcysteine granules was 5.5 million yuan, and the R&D investment for eprazole enteric tablets was 12.62 million yuan. Acetylcysteine granules obtained a drug registration certificate in June 2026. Iprazole enteric tablets have been registered for approval, and none of the above drugs have yet been produced or sold. This transaction does not constitute a related transaction, nor does it constitute a major asset restructuring. It does not require review and approval by the board of directors or shareholders' meeting within the authority of the chairman of the board of directors.